Back
Home hemodialysis (HHD) has not yet been adopted in Latin America. Fortunately, peritoneal dialysis (DP) is extensively used in Colombia as a cost-effective policy. However, in patients without option of DP, despite foreign data indicating HHD's cost-effectiveness compared to in center hemodialysis (HD), the low cost of conventional HD limit the introduction of HHD.
To determine the incremental cost-effectiveness ratio of HHD compared with HD in patients with home peritoneal dialysis contraindication or peritoneal membrane failure in Colombia. A Markov model was developed to assess the costs and health-related quality-adjusted life years (QALYs) of HHD compared to HD from the perspective of the Colombian healthcare system (direct medical costs) over a 5-year time horizon. Sensitivity analysis was performed with the effectiveness data, costs, and discount rates. Colombian pesos (COP) exchange to United States dollars (USD) was performed with an average rate of exchange during 2022 (1 USD = 4255.44) based on the official report of the Republic Bank of Colombia.
In the probabilistic analysis, HHD was associated with incremental costs of COP 110.333.580 (USD 25.927.6) and 0.31 QALYs, resulting in an incremental cost-effectiveness ratio of COP 351.816.435 (USD 82.674.5).
HHD does not appear to be cost-effective compared with HD from the perspective of a third-party payer in Colombia. However, an evaluation from a societal perspective is required to consider the reduction in indirect costs associated with HHD.